Form 4: Sarepta COO's Stock Withholding for Tax Obligations

Sarepta Therapeutics' Chief Operating Officer, Ian Michael Estepan, reported a disposition of 1,097 shares of common stock for tax withholding purposes.

Summary

• Ian Michael Estepan, Chief Operating Officer of Sarepta Therapeutics, Inc. (SRPT), reported a transaction on March 11, 2026.
• The transaction involved the disposition of 1,097 shares of Common Stock.
• These shares were withheld by Sarepta Therapeutics to satisfy tax withholding obligations.
• The tax obligations were related to the vesting of restricted stock units (RSUs) that were granted on March 10, 2025.
• The price per share for the disposed securities was $17.03.
• Following this transaction, Ian Michael Estepan beneficially owns 201,983 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard tax withholding transaction upon the vesting of restricted stock units, with no direct positive or negative implications for the company's operational performance or outlook.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that tax-related stock withholdings are a common practice for executives receiving equity compensation, reflecting the vesting of previously granted restricted stock units. This is a routine event in the biotech industry where equity compensation is prevalent.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation-related transaction and not a discretionary sale.
• Employees: Reflects the vesting of equity compensation for a key executive, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 reports a routine tax withholding transaction related to the vesting of restricted stock units for a company executive. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis.

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Tax Obligations, Ian Michael Estepan, Chief Operating Officer